The Fatima bint Mubarak Center at Cleveland Clinic Abu Dhabi, part of the M42 group, becomes the first center in the GCC region to participate in a groundbreaking global therapeutic clinical trial aimed at reducing the recurrence of breast cancer. Funded by AstraZeneca, the trial is evaluating
